US8236755 — Opioid depot formulations
Method of Use · Assigned to Camurus AB · Expires 2026-07-31 · 0y remaining
What this patent protects
This patent protects a method of using pre-formulations that contain an opioid bioactive agent, such as Subutex, to form a liquid crystalline phase structure upon contact with an aqueous fluid.
USPTO Abstract
The present invention relates to pre-formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein at least one opioid bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The preformulations are suitable for generating parenteral, non-parenteral and topical depot compositions for sustained release of active agents. The invention additionally relates to a method of delivery of an active agent comprising administration of a preformulation of the invention, a method of treatment comprising administration of a preformulation of the invention and the use of a preformulation of the invention in a method for the manufacture of a medicament. The method of treatments is especially for opioid addiction, dependence and/or withdrawal.
Drugs covered by this patent
- Subutex (BUPRENORPHINE) · Purdue Pharma Lp
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-3620 |
— | Subutex |
U-3620 |
— | Subutex |
U-3620 |
— | Subutex |
U-3620 |
— | Subutex |
U-3620 |
— | Subutex |
U-3620 |
— | Subutex |
U-3620 |
— | Subutex |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.